DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Serelaxin
Serelaxin
Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors
Future Diagnostic & Therapeutic Targets in Cardiorenal Syndromes
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Download
The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin
Jimmunol.1800856.Full.Pdf
ATC/DDD Classification
WO 2016/044447 Al 24 March 2016 (24.03.2016) P O P C T
Pharmacotherapies in Heart Failure with Preserved Ejection Fraction: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Reasanz; INN Serelaxin
Relaxin As a Therapeutic Target for the Cardiovascular Complications of Diabetes
Pharmacokinetics of Serelaxin in Patients With
Pharmacokinetics of Serelaxin in Patients with Severe Renal
Medicines Amendment Regulations 2018
Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute
Recent Advances and Future Directions in the Treatment of Heart Failure Focus of Pharmacological Therapy
Applications for New Human Medicines Under Evaluation by the Committee for Medicinal Products for Human Use August 2013
Top View
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
(INN) for Biological and Biotechnological Substances
E Cacy and Safety of Empagli Ozin Continuation in Patients with Type
2017HFA Congress
Moderna Inc Virtual Science Day on June 02, 2020 / 12:00PM
Cardioprotective Actions of Relaxin by Brian Joseph Martin BS, University
Journal.Pmed.1002248
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Research Article Total Chemical Synthesis of a Heterodimeric Interchain Bis-Lactam-Linked Peptide: Application to an Analogue of Human Insulin-Like Peptide 3
April 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Medicines and Related Substances Act No. 101 of 1965
Solving the Revolving Door Managing Heart Failure at Transitions of Care and Beyond Brent N
Human Relaxin-2 Attenuates Hepatic Steatosis and Fibrosis in Mice With
Older Americans, Please See Medi- See Please Ing Older Americans, Ameri- for Older Cines in Development
Medicines Amendment Regulations (No 2) 2015
Synthesis of Recombinant Human Relaxin H2 in Bacteria and Its Effects on Differentiation of Carcinoembryonic Stem Cells
WO 2017/152062 Al 8 September 2017 (08.09.2017) P O P C T
Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction—An Under-Recognized Clinical Entity
Optumrx Brand Pipeline Forecast
Medicines and Related Substances Act, 101 of 1965
Therapeutic Effects of Serelaxin in Acute Heart Failure – Necessity for Bilateral Research Translation – Xiao-Jun Du, MD, Phd; Tim D
Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
Serelaxin As a Potential Treatment for Renal Dysfunction in Cirrhosis: Preclinical Evaluation and Results of a Randomized Phase 2 Trial
Serelaxin in Clinical Development: Past, Present and Future
Heart Disease and Stroke
Total Chemical Synthesis of a Heterodimeric Interchain Bis-Lactam-Linked Peptide: Application to an Analogue of Human Insulin-Like Peptide 3
Effect of Orally Administered Relaxin in Experimental Nash
Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2
Biggest Launches 2014
Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats with Pulmonary Arterial Hypertension
DRAFT COMPARISON of the WHO ATC CLASSIFICATION & Ephmra
Shifts in Consensus Leave Novartis's Pipeline Both a Winner and a Loser
RLX030/Serelaxin
(INN) for Biological and Biotechnological Substances
( 12 ) United States Patent
Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why So Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?
Medicines Amendment Regulations (No 2) 2015
WO 2018/193408 Al 25 October 2018 (25.10.2018) W !P O PCT
The Cardiorenal Problem
NDO Home | Contact | Register for NDO Access
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Older Americans Affecting Diseases Chronic Top
Heart Failure Research Review TM
Serelaxin Elicits Bronchodilation and Enhances Β-Adrenoceptor-Mediated Airway Relaxation
Top 10 Pipelines
Enhanced Synthetic Methods and Stabilization of Insulin-Like Peptides